Monday, 25 Sep 2017

You are here

IV Golimumab in Psoriatic Arthritis

Simponi (golimumab) is approved by the FDA for use in rheumatoid arthritis, psoriatic arthritis (PsA), anklylosing spondylitis (AS) and ulcerative colitis. The intravenous (IV) formulation of golimumab (GOL) is approved for RA only.

Based on recent clinical trials, the makers of GOL have petitioned the FDA for new indications in PsA and AS. Trials for PsA (GO-VIBRANT) and AS (GO-ALIVE) were presented at last weeks EULAR 2017 meeting in Madrid, Spain.

The GO-VIBRANT trial results of IV GOL in PsA garnered enthusiastic reviews from KOLs and those in attendance. 

This phase 3 study was a multicenter, double-blind, placebo-controlled trial, of IV GOL in biologic-naïve adult PsA patients. They enrolled 480 patients to receive either placebo or Simponi Aria 2mg/kg at Weeks 0, 4, and every 8 weeks for 24 weeks. The primary endpoint was the ACR20 response at Week 14.

At Week 14, the ACR 20 responses were 75.1% GOL vs. 21.8% PBO. Similar, impressive ACR50 and ACR70 responses were seen at week 14. (43.6% and 24.5%, respectively). At week 24 the ACR 50 responses were superior to PBO (53.5% vs. 6.3%). Significant responses in enthesitis, dactylitis and skin were seen. The PASI75 responses were superior to PBO (59.2% vs. 13.6%).

At week 24 there was also significant inhibition of joint destruction and damage, joint erosion, and joint space narrowing compared to placebo.

There were 2 deaths, 2 malignancies, and 1 demyelinating event; no opportunistic infections or tuberculosis noted.

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Psoriasis Doubles Mortality Risk

Noe and colleagues have reported in the Journal of Investigative Dermatology that by estimating the extent of skin involvement in psoriasis (%BSA) they may assess future mortality risk. 

Psoriasis patients with 10% or more body surface area (BSA) involvement nearly doubled their risk of early death than those without the disease.

IV Golimumab Shines in Psoriatic Arthritis

Golimumab (GOL) is one of five marketed TNF inhibitors (TNFi) that is FDA approved for use in psoriatic arthritis (PsA). PsA approval was based on a 259 patient, randomized, controlled trial wherein GOL treated patients exhibited at week 24 ACR20/50/70 response of 52%, 32%, and 19%, respectively.

Therapeutic Update: 5 Questions on FDA Hearing for Tofacitinib in PsA

In this Therapeutic Update, Drs. Mease, Gibofsky and Cush answer five questions regarding the August 3rd FDA Arthritis Advisory Committee meeting that reviewed the potential approval of tofacitinib (Xeljanz) in patients with active psoriatic arthritis. The panel was nearly unanimous (10-1) in favor of the efficacy and safety profile of of tofacitinib, and similarly voted 10-1 to approve this drug for use in PsA. Final decisions on these recommendations from the AAC panel will be made at a later date by the FDA. 

Psoriatic Arthritis Patients with Comorbidities have Worse Disease and Poor Responses

A population-based cohort study shows that comorbidities in psoriatic arthritis patients (PsA) were associated with higher disease activity, shorter persistence and reduced clinical response to TNF inhibitors (TNFi). 

FDA Arthritis Advisory Panel Endorses Tofacitinib Approval for Psoriatic Arthritis

On Thursday, August 3, the FDA Arthritis Advisory Committee (AAC) met to consider tofacitinib for use in patients with psoriatic arthritis. The panel voted 10-1 in favor of approval.